Philippe Solal-Celigny
Overview
Explore the profile of Philippe Solal-Celigny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
3513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fischer L, Jiang L, Durig J, Schmidt C, Stilgenbauer S, Bouabdallah K, et al.
Leukemia
. 2024 Apr;
38(6):1307-1314.
PMID: 38678093
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy...
2.
Feugier P, Brice P, Maynadie M, Franchi-Rezgui P, Hacini M, Laurent G, et al.
Leuk Lymphoma
. 2018 Mar;
59(10):2485-2488.
PMID: 29486625
No abstract available.
3.
Solal-Celigny P, Leconte P, Bardet A, Hernandez J, Troussard X
Br J Haematol
. 2017 Dec;
180(2):217-223.
PMID: 29230799
Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory/relapsed follicular lymphoma patients, this study aimed to describe the real-life management of patients with refractory follicular...
4.
Voog E, Campion L, Du Rusquec P, Bourgeois H, Domont J, Denis F, et al.
Support Care Cancer
. 2017 Jul;
26(1):81-89.
PMID: 28756472
Purpose: Totally implantable venous access ports (TIVAP) have been widely used for many years in the management of patients suffering from cancer. The implantation and long-term use of TIVAPs are...
5.
Damaj G, Benbrahim O, Hacini M, Voronina I, Benabed K, Soumoudronga R, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Jun;
17(6):362-369.e2.
PMID: 28622961
Background: The ZOHé study was a prospective, observational, multicenter study in France to assess use of biosimilar filgrastim Zarzio in routine clinical practice in patients undergoing neutropenia-inducing chemotherapy. Patients And...
6.
Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al.
Lancet Haematol
. 2017 May;
4(6):e272-e282.
PMID: 28476440
Background: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation...
7.
Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, et al.
J Natl Cancer Inst
. 2017 Apr;
109(9).
PMID: 28423407
Background: The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes. It remains an...
8.
Solal-Celigny P
Expert Rev Hematol
. 2015 Mar;
8(2):147-53.
PMID: 25749209
Rituximab has become a keystone of the treatment of B-cell lymphoproliferation. The standard administration route is intravenous infusion with risks of infusion-related reactions. In order to make administration easier, increase...
9.
Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, et al.
Am J Hematol
. 2014 Jul;
89(11):1024-9.
PMID: 25052698
Treatment of primary central nervous system lymphoma (PCNSL) in elderly patients remains unsatisfactory. To develop a new high-dose methotrexate (HD-MTX)-based regimen including idarubicin, a phase 1 multicenter dose escalation study...
10.
Weisser M, Yeh R, Duchateau-Nguyen G, Palermo G, Nguyen T, Shi X, et al.
Blood
. 2014 Jun;
124(3):420-5.
PMID: 24916506
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from...